You just read:

Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer

News provided by

Syndax Pharmaceuticals, Inc.

Oct 25, 2018, 16:05 ET